Regen Ready to Launch Preclinical Studies on Lead Candidate RG-NAH005 as IBD Treatment

Regen Ready to Launch Preclinical Studies on Lead Candidate RG-NAH005 as IBD Treatment
Regen BioPharma, in collaboration with Zander Therapeutics, is preparing to launch preclinical studies on its lead candidate RG-NAH005 for inflammatory bowel disease (IBD), the company announced in a press release. RG-NAH005 is a small molecule that promotes the activity of the NR2F6 receptor in immune cells. The NR2F6 receptor has been recognized as a critical

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *